Company profile

BAXTER INTERNATIONAL INC

NYSE:BAXMedical/Dental Instruments

Drug pipeline (124)

AssetStageRevenueTrialsStatus
Acetaminophenapproved78approved
Acetic Acidapproved0
Aminocaproic Acidapproved0
Amiodarone hydrochlorideapproved0
ARGATROBANapproved0

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (36)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT06842121phase1completed2025-01-272025-05-22Baxter Healthcare CorporationA Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)
NCT00358553phase1completedBaxter Healthcare CorporationA Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin
NCT06842134phase1completed2025-01-272025-05-22Baxter Healthcare CorporationA Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E
NCT00508495phase3completed2007-08-012008-03-01Baxter Healthcare CorporationAnalgesic Efficacy, Safety and Tolerability of Two Paracetamol-Containing Solutions in Post-Surgical Hip Replacement Pain
NCT00406679phase3completed2006-11-012007-10-01Baxter Healthcare CorporationAnalgesic Efficacy, Safety and Tolerability of Two Paracetamol-containing Solutions in Post-Surgical Dental Pain

FDA applications (233)

ApplicationTypeApplicantProducts
ANDA 020360ANDABAXTER HEALTHCARE CORP
ANDA 020512ANDABAXTER HEALTHCARE CORP
ANDA 040745ANDABAXTER HEALTHCARE CORP
ANDA 040859ANDABAXTER HEALTHCARE CORP
ANDA 062373ANDABAXTER HEALTHCARE CORP